REPOSITIONING INTELLIGENCE — EVIDENCE REPORT
============================================
Generated: Nov 12, 2026, 11:44 PM UTC

DISCLAIMER: This report is for research and informational use only.
It is NOT medical advice, diagnosis, or treatment guidance.

DRUG–DISEASE PAIRING
--------------------
Drug:     Metformin
Disease:  Breast Cancer
Target:   AMP-activated protein kinase

EVIDENCE GRADE: Moderate Evidence
Confidence Score: 62%
Evidence Level: Level 2b–3 (observational + preclinical)
Trial Phase: Phase II

MECHANISM
---------
AMPK activation suppresses mTOR-mediated proliferation in breast epithelial cells.

OUTCOMES
--------
Observational studies suggest reduced cancer incidence; RCTs in adjuvant setting show mixed results.

AI SUMMARY (generated March 15, 2026)
-----------
Metformin shows mechanistic plausibility and epidemiological support for breast cancer risk reduction, but prospective RCT evidence in treatment-naïve adjuvant settings remains inconclusive. Suitable for hypothesis generation and trial design, not clinical recommendation outside diabetes care.

KNOWN RISKS
-----------
• Lactic acidosis (rare, especially with renal impairment)
• GI upset
• Vitamin B12 deficiency with long-term use
• Contraindicated in severe renal dysfunction

CITATIONS
---------
[PUBMED] 22019127: Metformin and cancer risk in diabetic patients
  https://pubmed.ncbi.nlm.nih.gov/22019127/

[PUBMED] 23487376: Metformin and breast cancer: a systematic review
  https://pubmed.ncbi.nlm.nih.gov/23487376/

[CLINICALTRIALS] NCT01101438: Metformin in early breast cancer (MA.32)
  https://clinicaltrials.gov/study/NCT01101438

PUBMED IDs: 22019127, 23487376
CLINICAL TRIAL IDs: NCT01101438

LAST VERIFIED: June 28, 2026
LAST UPDATED:  June 28, 2026
REVIEW STAGE:  published

---
Repositioning Intelligence Platform · Research Mode